检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]广西桂林医学院附属医院眼科,541004 [2]广西桂林医学院,541004
出 处:《实用医学杂志》2014年第4期518-522,共5页The Journal of Practical Medicine
基 金:广西自然科学基金项目(编号:KY2012021(2012GXNSFAA053103);广西科学实验中心开放课题项目(编号:KFJJ2011-11)
摘 要:目的:研究PDGF-α受体反义寡核苷酸对实验性增殖性玻璃体视网膜病变(PVR)的防治作用。方法:选择PDGFR-αASODN/lip2000比值1∶1、1∶2.5、1∶5制备复合物转染至HRPE细胞中24 h后注射入家兔玻璃体腔。PVR模型健康成年有色家兔24只随机分为人视网膜色素上皮(HRPE)细胞稀释液组(A组)、1.0与2.0μmol/LPDGFR-αASODN脂质体转染的RPE细胞稀释液组(B组和C组),每组8只眼。间接眼底镜观察PVR程度;组织病理学观察眼底改变;免疫组织化学染色观察PDGFA浓度。结果:当PDGFR-αASODN/lip2000比值为1∶2.5时,HRPE细胞最佳转染效率。B组和C组PVR程度、组织病理学改变、免疫组织化学染色PDGFA浓度低于A组,C组比B组更低。结论:PDGF-α受体反义寡核苷酸能够抑制实验性增殖性玻璃体视网膜病变的发生发展。Objective To examine the effect of PDGF-α receptor on proliferative vitreoretinopathy (PVR) in rabbits. Methods Different concentrations of PDGFR-α ASODN were mixed with lip 2000, and the final proportion of PDGFR-α ASODN/lip2000 complex was 1 : 1,1 : 2.5 and 1 : 5 respectively. All the complexes were incubated with cultured human retinal pigment epithelium for 24 hours before transfection. The rabbits were divided into group A (RPE cells),group B and C (1.0,2.0 μmol/L PDGFR-α ASODN lipofectin transfection of RPE cells) with 8 eyes each. The level of PVR were estimated by indirect ophthalmoscope examination; the fundus changes were estimated by histopathology ; and the expression of PDGFA was detected by immunohistochemistry. Results The highest transduction efficiency was PDGFR-α ASODN/ lip2000 ratio to 1 : 2.5. The degree of proliferative vitreoretinopath, the fundus changes and the density of PDGFA in group B and group C were significantly lower than that in group A, while group C more lower than group B. Conclusion PDGF-α receptor antisense oligonucleotides can inhibit the development of experimental proliferative vitreoretinopathy.
关 键 词:增殖性玻璃体视网膜病变 视网膜色素上皮细胞 PDGF-α受体 反义寡核苷酸
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:13.59.205.74